Cancer Genetics Testing Firm NeoGenomics Eyes $7.8M from Public Offering of Stock | GenomeWeb

NEW YORK (GenomeWeb News) – NeoGenomics today announced the public offering of 3.15 million shares of its common stock at $3.00 per share.

The Ft. Myers, Fla.-based firm which specializes in cancer genetic testing, is selling 2.85 million shares, while a shareholder, the Mary S. Dent Gifting Trust, will sell 300,000 shares.

NeoGenomics expects to raise $7.8 million in net proceeds from the offering. It will not receive any proceeds from Mary S. Dent's sale of its shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.